血清Renalase水平对不同分期慢性肾脏疾病的诊断价值

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-08-20 DOI:10.1016/j.cca.2025.120561

Siwen Yu , Yanhua Wang , Wenchao Fei , Ke Xu , Xiaolin Wu , Yinghua Li

{"title":"血清Renalase水平对不同分期慢性肾脏疾病的诊断价值","authors":"Siwen Yu , Yanhua Wang , Wenchao Fei , Ke Xu , Xiaolin Wu , Yinghua Li","doi":"10.1016/j.cca.2025.120561","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>The study aimed to explore the role of renalase in chronic kidney disease (CKD) and establish a diagnostic cutoff value for chronic kidney disease (CKD).</div></div><div><h3>Methods</h3><div>Researchers analyzed serum renalase levels in 44 healthy adults and 250 CKD patients across stages I to V, along with other kidney function indicators like blood urea nitrogen (BUN), serum creatinine (CRE), uric acid (UA), Cystatin-C (Cys-C), β2-microglobulin (β2-mg), and estimated glomerular filtration rate (eGFR).</div></div><div><h3>Results</h3><div>Serum renalase concentrations progressively increased from stage I to V CKD patients, significantly correlating with advancing renal dysfunction. Strong correlations were found between renalase and age, CRE, eGFR, UA, Cys-C, BUN, β2-mg, and CKD stage (all <em>P</em> < 0.001), but not with gender. Notably, the receiver operating characteristic (ROC) curve analysis highlighted stage II CKD, with an AUC of 0.980 for renalase, suggesting a diagnostic threshold of 6.595 μg/ml, offering 89.3 % sensitivity and 98.6 % specificity.</div></div><div><h3>Conclusions</h3><div>These results underscore serum renalase as a sensitive indicator for early-stage CKD diagnosis, complementing current biomarkers in detecting kidney impairment. Thus, renalase emerges as a promising novel biomarker need further investigation in more extensive cohorts for enhancing early CKD prediction capabilities.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120561"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The diagnostic value of Renalase level in serum for chronic kidney disease with different stages\",\"authors\":\"Siwen Yu , Yanhua Wang , Wenchao Fei , Ke Xu , Xiaolin Wu , Yinghua Li\",\"doi\":\"10.1016/j.cca.2025.120561\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>The study aimed to explore the role of renalase in chronic kidney disease (CKD) and establish a diagnostic cutoff value for chronic kidney disease (CKD).</div></div><div><h3>Methods</h3><div>Researchers analyzed serum renalase levels in 44 healthy adults and 250 CKD patients across stages I to V, along with other kidney function indicators like blood urea nitrogen (BUN), serum creatinine (CRE), uric acid (UA), Cystatin-C (Cys-C), β2-microglobulin (β2-mg), and estimated glomerular filtration rate (eGFR).</div></div><div><h3>Results</h3><div>Serum renalase concentrations progressively increased from stage I to V CKD patients, significantly correlating with advancing renal dysfunction. Strong correlations were found between renalase and age, CRE, eGFR, UA, Cys-C, BUN, β2-mg, and CKD stage (all <em>P</em> < 0.001), but not with gender. Notably, the receiver operating characteristic (ROC) curve analysis highlighted stage II CKD, with an AUC of 0.980 for renalase, suggesting a diagnostic threshold of 6.595 μg/ml, offering 89.3 % sensitivity and 98.6 % specificity.</div></div><div><h3>Conclusions</h3><div>These results underscore serum renalase as a sensitive indicator for early-stage CKD diagnosis, complementing current biomarkers in detecting kidney impairment. Thus, renalase emerges as a promising novel biomarker need further investigation in more extensive cohorts for enhancing early CKD prediction capabilities.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"578 \",\"pages\":\"Article 120561\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898125004401\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125004401","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的探讨肾化酶在慢性肾脏疾病（CKD）中的作用，建立慢性肾脏疾病（CKD）的诊断临界值。研究人员分析了44名健康成人和250名I - V期CKD患者的血清renalase水平，以及其他肾功能指标，如血尿素氮（BUN）、血清肌酐（CRE）、尿酸（UA）、胱他汀- c （cysc）、β2-微球蛋白（β2-mg）和肾小球滤过率（eGFR）。结果从I期到V期CKD患者血清renalase浓度逐渐升高，与肾功能恶化显著相关。renalase与年龄、CRE、eGFR、UA、Cys-C、BUN、β2-mg和CKD分期之间存在很强的相关性（P均为0.001），但与性别无关。值得注意的是，受试者工作特征（ROC）曲线分析突出了II期CKD， renalase的AUC为0.980，提示诊断阈值为6.595 μg/ml，灵敏度为89.3%，特异性为98.6%。结论血清renalase可作为早期CKD诊断的敏感指标，补充了目前检测肾脏损害的生物标志物。因此，renalase作为一种有前景的新型生物标志物需要在更广泛的队列中进一步研究，以增强早期CKD的预测能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The diagnostic value of Renalase level in serum for chronic kidney disease with different stages

Objectives

The study aimed to explore the role of renalase in chronic kidney disease (CKD) and establish a diagnostic cutoff value for chronic kidney disease (CKD).

Methods

Researchers analyzed serum renalase levels in 44 healthy adults and 250 CKD patients across stages I to V, along with other kidney function indicators like blood urea nitrogen (BUN), serum creatinine (CRE), uric acid (UA), Cystatin-C (Cys-C), β2-microglobulin (β2-mg), and estimated glomerular filtration rate (eGFR).

Results

Serum renalase concentrations progressively increased from stage I to V CKD patients, significantly correlating with advancing renal dysfunction. Strong correlations were found between renalase and age, CRE, eGFR, UA, Cys-C, BUN, β2-mg, and CKD stage (all P < 0.001), but not with gender. Notably, the receiver operating characteristic (ROC) curve analysis highlighted stage II CKD, with an AUC of 0.980 for renalase, suggesting a diagnostic threshold of 6.595 μg/ml, offering 89.3 % sensitivity and 98.6 % specificity.

Conclusions

These results underscore serum renalase as a sensitive indicator for early-stage CKD diagnosis, complementing current biomarkers in detecting kidney impairment. Thus, renalase emerges as a promising novel biomarker need further investigation in more extensive cohorts for enhancing early CKD prediction capabilities.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.